Dexibuprofen slow-release capsule and production method thereof

Abstract

The invention discloses a dexibuprofen slow-release capsule. Pellets are filled in the capsule, each pellet consists of a pellet core and four layers of materials wrapped outside the pellet core, the four layers of materials are sequentially an inner isolation layer, a first coating layer, a second coating layer and a third coating layer from inside to outside, and the pellet core, the inner isolation layer, the first coating layer, the second coating layer and the third coating layer respectively have the following compositions: the pellet core is prepared by medicine auxiliary materials, the inner isolation layer is stearic acid, the first coating layer is a coating mixture, the second coating layer comprises the coating mixture and the stearic acid, the third coating layer is the coating mixture, and the coating mixture consists of dexibuprofen and polyvidone K30. The invention also provides a production method of the dexibuprofen slow-release capsule. Compared with an ordinary capsule, the dexibuprofen slow-release capsule disclosed by the invention has the same absorption degree, but the dexibuprofen blood maximum concentration (Cmax) of the dexibuprofen slow-release capsule disclosed by the invention in human bodies is lower, the maximum time (Tmax) from the administration to the blood Cmax reaching is longer, and a good slow release effect is realized.

Description

technical field [0001] The invention relates to a dextrobuprofen sustained-release capsule and a production method thereof. Background technique [0002] Dexibuprofen is the S(+)-isomer of ibuprofen, which was launched in Austria in 1994. Its activity is 160 times that of the L-isomer and 1.6 times that of the racemate. Ibuprofen is composed of equal amounts of dextrorotary and levorotatory forms. It has been clinically used for 30 years. It is one of the most common NSAIDs in clinical use and is considered to be the safest non-steroidal anti-inflammatory drug ( NSAIDs) were approved as OTC drugs by the US FDA in 1984. Clinical data show that dextroibuprofen has a faster onset of action than racemic ibuprofen, with the same mechanism of action but better pharmacological effects. It is a non-selective cyclooxygenase (COX) inhibitor and is widely used in therapeutic classes. Rheumatic diseases, as well as joint and muscle pain, headache, dysmenorrhea and other pains. [00...

AI Technical Summary

Problems solved by technology

Many times of taking medicine not only increases the burden of the patient, but also the concentration of Dexibuprofen in the patient's blood changes greatly, and the side effects are also large.